Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICE

Melanie Y. Bertram * , Jeremy A. Lauer , Karin Stenberg , Tessa Tan Torres Edejer

Cited by CrossRef:

1- Yang Y, Yu J, Zhu Z, Li Y, Xiao Z, Zhi C, Xie Z, Kang Y, Li J, Zhou B. Comparison of clinical outcomes and cost-utility between unilateral biportal endoscopic discectomy and percutaneous endoscopic interlaminar discectomy for single-level lumbar disc herniation: a retrospective matched controlled study. J Orthop Surg Res. 2024;19(1) [Crossref]

2- Ge X, Cui K, Ma H, Zhao S, Meng W, Wang W. Cost-effectiveness of comprehensive preventive measures for coal workers’ pneumoconiosis in China. BMC Health Serv Res. 2022;22(1) [Crossref]

3- Zhang X, Shen P, Liu J, Ji X, Su K, Hu R, Chen C, Fang H, Jin X, Lin H, Sun Y, Yan L. Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses. Vaccine. 2023;41(34):5045 [Crossref]

4- Guan Y, Ru N, Kang R, Jia X, Xu T, Meng Z, Nashwan A. A Systematic Review of Economic Evaluations in Clinical Nursing Practices. Journal of Nursing Management. 2024;2024(1) [Crossref]

5- Baek Y, Fisher J, Tran T, Owen A, Nguyen T, Luchters S, Hipgrave D, Hanieh S, Tran T, Ha T, Biggs B, Ademi Z. Economic returns on investing in early childhood development in Vietnam: a cost-benefit analysis. BMC Health Serv Res. 2025;25(1) [Crossref]

6- Drake T, Chi Y, Morton A, Pitt C. Why cost-effectiveness thresholds for global health donors differ from thresholds for Ministries of Health (and why it matters). F1000Res. 2023;12:214 [Crossref]

7- Gorelova M, Donin G, Kneppo P. Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI. Health Technol. 2025;15(2):377 [Crossref]

8- Qaseem A, Obley A, Shamliyan T, Hicks L, Harrod C, Crandall C, Balk E, Cooney T, Cross J, Fitterman N, Lin J, Maroto M, Miller M, Shekelle P, Tice J, Tufte J, Etxeandia-Ikobaltzeta I, Yost J, Qaseem A, Obley A, Shamliyan T, Hicks L, Harrod C, Crandall C, Wilt T, Owens D, Carroll K, Balk E, Cooney T, Cross J, Fitterman N, Lin J, Maroto M, Miller M, Shekelle P, Tice J, Tufte J, Etxeandia-Ikobaltzeta I, Yost J. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024;177(5):658 [Crossref]

9- Russo P. How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality. Grhta. 2022;9:31 [Crossref]

10- Hijazi W, Vandenberk B, Rennert-May E, Quinn A, Sumner G, Chew D. Economic evaluation in cardiac electrophysiology: Determining the value of emerging technologies. Front Cardiovasc Med. 2023;10 [Crossref]

11- Cheung T, Cheng S, Hsu D, Wing-Lei Wong Q, Pavelyev A, Sukarom I, Saxena K. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong. Human Vaccines & Immunotherapeutics. 2023;19(2) [Crossref]

12- Abuhadida S. Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait. EUROPEAN J ENV PUBLI. 2022;6(2):em0120 [Crossref]

13- Drake T, Chi Y, Morton A, Pitt C. Why cost-effectiveness thresholds for global health donors should differ from thresholds for Ministries of Health (and why it matters). F1000Res. 2024;12:214 [Crossref]

14- He J, Wang W, Ning P, Schwebel D, Yang Y, Cheng P, Li J, Zhao M, Li W, Zhang N, Liu H, Hu G. Evaluating the effectiveness of the safety experience room, an affordable interactive education intervention to prevent unintentional injury among rural preschoolers in China: protocol for a cluster randomized controlled trial. BMC Public Health. 2023;23(1) [Crossref]

15- Tchouaket É, Sia D, Karemere H, Kapiteni W, Robins S. Analyse économique d’un programme de renforcement du système de santé en République démocratique du Congo. 2024;36(1):135 [Crossref]

16- Dzingirai B, Katsidzira L, Mwanesani V, Postma M, van Hulst M, Mafirakureva N. A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe. Expert Review of Pharmacoeconomics & Outcomes Research. 2024;24(5):687 [Crossref]

17- Empringham B, Karellis A, Fernandez-Suarez M, Carmona S, Pai N, Zwerling A. Understanding the cost-utility of implementing HIV self-testing with digital-based supports. Front Public Health. 2025;12 [Crossref]

18- Hailu A, Eregata G, Yigezu A, Bertram M, Johansson K, Norheim O. Contextualization of cost-effectiveness evidence from literature for 382 health interventions for the Ethiopian essential health services package revision. Cost Eff Resour Alloc. 2021;19(1) [Crossref]

19- Lin S, Yang S, Wu T, Wang J, Liu L. Estimation of disability free life expectancy in non small cell lung cancer based on real world data. Sci Rep. 2023;13(1) [Crossref]

20- Zhang H, Fink G, Cohen J. Malaria Rapid Tests, Febrile Illness Management, and Child Mortality Across Sub-Saharan African Countries. JAMA. 2024;332(15):1270 [Crossref]

21- Yuasa A, Yonemoto N, Kamei K, Murofushi T, LoPresti M, Taneja A, Horgan J, Ikeda S. Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. Adv Ther. 2022;39(12):5327 [Crossref]

22- Hachicha-Maalej N, Lepers C, Collins I, Mostafa A, Ades A, Judd A, Scott K, Gibb D, Pett S, Indolfi G, Yazdanpanah Y, El Sayed M, Deuffic-Burban S. Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egypt: a cost-effectiveness study. bmjph. 2024;2(1):e000517 [Crossref]

23- Tran J, Hathaway C, Broshkevitch C, Palanee-Phillips T, Barnabas R, Rao D, Sharma M. Cost-effectiveness of single-visit cervical cancer screening in KwaZulu-Natal, South Africa: a model-based analysis accounting for the HIV epidemic. Front Oncol. 2024;14 [Crossref]

24- Tordrup D, Smith R, Kamenov K, Bertram M, Green N, Chadha S. Global return on investment and cost-effectiveness of WHO's HEAR interventions for hearing loss: a modelling study. The Lancet Global Health. 2022;10(1):e52 [Crossref]

25- Dawkins B, Shinkins B, Ensor T, Jayne D, Meads D. Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines. Int J Technol Assess Health Care. 2024;40(1) [Crossref]

26- Abuhadida S, Bastaki L, Bash B, Alhindal B. Return on Investment from the Prevention of Orphan Diseases in Kuwait. Ann Public Health. 2022; [Crossref]

27- Tomeny E, Hampton T, Tran P, Rosu L, Phiri M, Haigh K, Nidoi J, Wingfield T, Worrall E. Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses. PharmacoEconomics. 2024;42(11):1209 [Crossref]

28- Teigen D, Opoka R, Kasirye P, Nabaggala C, Hume H, Blomberg B, John C, Ware R, Robberstad B. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. PharmacoEconomics. 2023;41(12):1603 [Crossref]

29- Gómez-Palomo J, Martínez-Crespo A, Passini-Sánchez J, Ignatyev-Simonov N, Zamora-Navas P, Guerado E. Quality of life and cost-utility analysis in patients with femoral neck fracture: a propensity score matching study comparing monopolar hemiarthroplasty and total hip arthroplasty. Qual Life Res. 2025; [Crossref]

Submit Your Paper Archive